Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00719043 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 841
- Enrollment target
NCT00719043 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 841 participants.
The verdict
NCT00719043, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 841 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic and safe when given to adults aged \>=18 years. This Protocol Posting has been updated following Amendments 1-3 of the Protocol, Dec 2009. The impacted sections are study design and outcome measures.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
- BIOLOGICAL A/turkey H5N1 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 841 participants |
| Start Date | 2008-07-11 |
| Est. Completion | 2011-02-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00719043
The ClinicalTrials.gov registry entry for NCT00719043 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 841 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00719043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00719043 about?
NCT00719043 is a clinical study titled "Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years". The purpose of this study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic and safe when given to adults aged \>=18 years. This Protocol Posting has been updated following Amendments 1-3 of the Protocol, Dec 2009. The impacted sections are study design and outcome measure...
What is the current status of trial NCT00719043?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 841 participants. The study started on 2008-07-11. Estimated completion is 2011-02-18.
What interventions are being tested in trial NCT00719043?
The interventions under investigation include: Placebo (BIOLOGICAL), Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) (BIOLOGICAL), A/turkey H5N1 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00719043?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.